Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial ...

Digitalis is one of the oldest medicines in the cardiovascular arsenal. When William Withering identified digitalis as the active ingredient in the foxglove plant more than 200 years ago he was only ...

FDA: Stress Test Agents Linked to Possible Heart Attack, Death Previous research has yielded conflicting evidence on the use of digoxin in patient with atrial fibrillation (AF) or congestive heart ...

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20 percent, according to recent results. The findings suggest that caution may be needed when using ...

However, compared with patients not on digoxin, patients with a serum digoxin concentration ≥1.2 ng/mL had a 56% increased hazard of mortality (adjusted HR, 1.56; 95% confidence interval, 1.2 to 2.04) ...

A study from the University of Birmingham, UK, has indicated that the use of digoxin could lead to substantial cost savings for the National Health Service (NHS) when treating senior individuals with ...

OAKLAND, CA — Introduction of digoxin therapy in patients with new systolic heart failure was associated with a significant 72% jump in all-cause mortality but no effect on HF-hospitalization risk in ...

Digoxin used to treat patients with irregular heart beat rate has not been as rigorously tested as other drugs. Reuters Yet another study has shown that digoxin, a drug commonly used to treat patients ...

Protective effects have been suggested for digoxin against prostate cancer risk. However, few studies have evaluated the possible effects on prostate cancer-specific survival. We studied the ...

SEVILLE, SPAIN — Weighing in on the current debate over whether the benefits of using digoxin are worth its perceived dangers in patients with atrial fibrillation (AF) and/or heart failure (HF), new ...

Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial. This is an ASCO Meeting Abstract from ...